HCPCS Code Descriptor:
Injection, pegfilgrastim-apgf (nyvepria), biosimilar, 0.5 mg
Oncology Biosimilar Colony Stimulating Factor
Route of Administration:
NYVEPRIA is an Oncology Biosimilar Colony Stimulating Factor drug manufactured by Pfizer and administered via the Subcutaneous route of administration. The Q Code: Q5122 is aligned to the drug NYVEPRIA.
Nyvepria (pegfilgrastim) is a man-made protein that aids in the production of certain white blood cells (neutrophils). This medication can be used as a preventative measure to ensure that a patient doesn’t have a deficiency of neutrophils. Nyvepria is produced by Pfizer and is a biosimilar to the medication Neulasta (J2506). Nyvepria has been aligned to the HCPCS code Q5122 since January 2021.
Access Pricing and More By Registering
HCPCS Added Date:
HCPCS Effective Date:
HCPCS Short Description:
Billing and Coding Guide: